Showing results (71-80 of 98) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 2, 2005
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trialNorio Kohno, Kenjiro Aogi, Hironobu Minami, et al.
Japanese Journal of Clinical Oncology|November 11, 2008
Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imagingNaruto Taira, Shozo Ohsumi, Daisuke Takabatake, et al.
Japanese Journal of Clinical Oncology|May 27, 2008
Contrast-enhanced CT evaluation of clinically and mammographically occult multiple breast tumors in women with unilateral early breast cancerNaruto Taira, Shozo Ohsumi, Daisuke Takabatake, et al.
The Journal of Steroid Biochemistry and Molecular Biology|November 19, 2003
Role of steroid sulfatase in local formation of estrogen in post-menopausal breast cancer patientsTaisuke Nakata, Shigemitsu Takashima, Yukimasa Shiotsu, et al.
Japanese Journal of Clinical Oncology|September 25, 2009
Phase II study of gemcitabine monotherapy as a salvage treatment for Japanese metastatic breast cancer patients after anthracycline and taxane treatmentYasuhiro Suzuki, Yutaka Tokuda, Yasuhiro Fujiwara, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 4, 2002
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group]Rikiya Abe, Takeshi Tominaga, Tadashi Nomizu, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|June 4, 2002
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group]Izo Kimijima, Takeshi Tominaga, Tadashi Nomizu, et al.
Breast Cancer Research and Treatment|August 2, 2011
First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese studyKenjiro Aogi, Norikazu Masuda, Shinji Ohno, et al.
Breast Cancer (Tokyo, Japan)|September 13, 2012
Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancerMorihiko Kimura, Takeshi Tominaga, Izo Kimijima, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|April 30, 2002
[CGS 20267 (Letrozole), a new aromatase inhibitor: early phase II study for postmenopausal women with advanced breast cancer]Yasuo Nomura, Takeshi Tominaga, Kouji Enomoto, et al.
Pageof 10